Preclinical Oncology Models Market Detailed Analysis and Forecast to 2030

According to the latest market intelligence research report by InsightAce Analytic, the global preclinical oncology models market size was valued at US$ 1,020.2 Million in 2021, and it is expected to reach US$ 2,463.7 Million in 2030, recording a promising CAGR of 10.6% from 2022 to 2030.

Request Free Sample Copy of Report: https://www.insightaceanalytic.com/request-sample/1093

Scientists require preclinical oncology models for predicting the clinical efficacy of novel anticancer agents. The increased demand for cancer immunotherapy has provoked various preclinical and translational challenges. Hence, there is a high need for preclinical models to screen anticancer agents with robust clinical correlation accurately.
The advances in immuno-oncology, surging targeted and novel cancer therapies, increasing R&D activities in oncology and drug development, high demand for robust preclinical oncology models such as humanized & syngeneic tumor models, and the rising need to reduce translational failures in clinical trials are expected to stimulate the market growth over the forecast period. Apart from this, early identification of predictive biomarkers and the need for the rational design of combination therapies also boost the expansion of the preclinical oncology models market.

Preview for Detailed TOC: https://www.insightaceanalytic.com/report/global-preclinical-oncology-models-market/1093

The prominent players in the preclinical oncology models industry include:

Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI Bioresearch Inc, Pharmatest Services, Taconic Biosciences, Inc., The Jackson Laboratory, and Other Prominent Players.

Key Industry Developments from Leading Players:

• In Dec 2021, Crown Bioscience, a leading contract research organization (CRO) in preclinical and translational drug development services, expanded its Crown Bioscience United Kingdom facility. This expansion offers additional imaging modalities to visualize better and understand tumor progression and response to potential therapies. The additional imaging platform allows performing cutting-edge preclinical studies, offering advanced insights on potential drug candidates before clinical trials.

• In Feb 2021, Charles River Laboratories International, Inc. partnered with Kibur Medical to provide exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies.

• In May 2020, BioDuro, LLC, a leading drug discovery and development services organization, announced the availability of two new preclinical models for Non-alcoholic steatohepatitis (NASH) that highly resemble the clinical progression of the disease. The models include mouse and hamster species and manifest all the hallmarks of NASH disease, enabling drug developers to evaluate broad classes of drug targets, including metabolic inflammation and fibrogenic pathways alike.

Preclinical Oncology Models Market Regional Analysis:

North America is expected to be the most lucrative region of this market in the forecast years, owing to the high demand for cancer immunotherapies, increasing research funding for oncology, and the need for preclinical oncology models.

The Asia Pacific is estimated to proliferate during the analysis of the forecast period. The technological advancement in cancer diagnostic techniques & treatment, high demand for targeted therapies, and the increasing R&D initiatives in oncology clinical trials by industry players are the factors responsible for the regional market growth.

Inquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1093

The Global Preclinical Oncology Models Market Segments

The Global Preclinical Oncology Models Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2019 to 2030 based on Product
• Patient-Derived Xenograft Models (PDX)
• Cell Line Derived Xenograft Models
• Syngeneic Models
• Genetically engineered mouse models (GEMMs)
• Orthotopic Models
• Custom Xenograft and Syngeneic Model
• Others

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.

Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Email: info@insightaceanalytic.com

This release was published on openPR.